… This systematic review aimed to assess the tolerability of patients with cardiac
amyloidosis (CA) to beta-blockers (BBs) and evaluate its association with adverse outcomes. …

… Cardiac amyloidosis (CA) typically manifests as a restrictive … and occasionally used in
these patients, we investigated utilization and tolerance of BB in a cohort of patients with AL CA. …

… at all, such as amyloidosis, and managing concurrent … , beta blockers were proposed.
In addition, the demographic of … function, symptoms, exercise tolerance and hemodynamic …

… Systemic amyloidosis due to accumulation of misfolded transthyretin (TTR) protein causes
cardiomyopathy in approximately 50 000 to 150 000 people in the US. TTR, also known as …

… In this retrospective cohort study of 82 patients with AL or ATTR cardiac amyloidosis and …
the safety and efficacy of traditional HF therapies. The main findings of our study were: (1) BB, …

… A systematic review of the literature was performed to identify all clinical trials evaluating
beta-blockers' efficacy in HF. Eligible studies had to be randomized, placebo-controlled and …

… Beta blockers may prevent the increased heart rate that physiologically compensates for
diminishing stroke volume. Angiotensin-converting enzyme inhibitors and angiotensin …

… Similarly, β-blockers, especially at higher dosages and those with accompanying α-blocking …
not well tolerated by patients with cardiac amyloidosis. As cardiac amyloidosis progresses, …

… We performed a systematic review of peer-reviewed publications that were identified through
… Preliminary open-label studies are in progress to study safety and tolerability and optimize …

… They aim to analyze if the drug can slow or stop the progression of TTR amyloid
cardiomyopathy and determine the tolerability and safety over 24 months (NCT03702829). …